Your Cart Is Empty
✖No products in the cart.
Our advanced technologies enable accurate quantification and expression profiling of DNA, RNA, and proteins using very small sample volumes—sometimes as little as 1–100 cells or 1 μL of plasma or serum. This approach makes it possible to generate high-quality data from limited or precious samples that are often not feasible for traditional methods like LC-MS/MS, Western blot, HPLC, or flow cytometry.
Biological responses, such as protein and mRNA expression or post-translational modifications, can shift rapidly after treatment or surgical intervention. By combining standardized protocols with rapid, controlled tissue processing, we capture these dynamic changes in real time. Our minimally invasive or non-invasive sampling methods provide accurate insights into molecular responses before, during, and after administration—supporting more rational drug dosing strategies and efficacy evaluation.
Through coordinated PK/PD applications and sensitive assays, we can extract richer data while reducing animal usage. Using core or fine-needle aspirate biopsies in preclinical and clinical studies, our approach minimizes the need for large animal cohorts by enabling longitudinal studies from repeated small samples. This reduces animal sacrifice while delivering high-resolution insights into protein changes, target engagement, and drug resistance development.
Proteins and their regulators are often overlooked due to technical challenges or large sample requirements. Our validated technologies allow highly sensitive detection of proteins, signaling pathways, and transcriptional regulation (mRNA stability, post-translational modifications, phosphorylation) from minimal inputs. This provides a direct window into disease mechanisms and biomarker discovery with cost-effective, reliable assays.
We offer multiplexed analysis of cytokines, chemokines, tumor suppressors, and other signaling molecules—up to 150-plex—without compromising specificity or sensitivity. This enables broad profiling from limited samples, providing deeper biological insights.
Unlike traditional Western blotting, which is semi-quantitative and variable, our assays deliver precise, quantitative results. Using ELISAs, FACS, and other high-sensitivity methods, we measure absolute protein amounts—even at low picogram per milliliter (pg/mL) levels—while still preserving qualitative insights into expression patterns.
Our assay portfolio is designed to accommodate a wide range of research needs—from small or scarce samples to complex, high-throughput projects. We offer solutions for single-cell analysis, protein, mRNA, and microRNA detection, as well as customizable workflows. Combined with our ready-to-use in vitro models, primary cell lines, and bioanalytical platforms, we support both early drug discovery and preclinical development with unmatched flexibility.
No products in the cart.